The Synergistic and Anticancer Potential of Withania Somnifera (Ashwagandha) Ethanol Extract as an Adjuvant with Doxorubicin in MCF7 Breast Cancer Cell Line
Elzayat EM, Elsamahy GE, Mansour GH, El-Sherif AA, Hassan N
Asian Pacific journal of cancer prevention : APJCP · 5 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-03-01 · Asian Pac J Cancer Prev · vol. 26 · número 3 · págs. 757–766
- Editorial
- West Asia Organization for Cancer Prevention
- Citado
- 8 citas · más que el 98% de estudios similares · 9.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 2 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Andrographolide Research and Applications · Cell death mechanisms and regulation
- Palabras clave
- Withania somnifera, MCF-7, Doxorubicin, Traditional medicine, Adjuvant, Cancer cell lines, Breast cancer, Chemistry, Cell culture, Pharmacology, Ethanol, Cancer, Medicine, Biology, Human breast, Cancer cell, Oncology, Biochemistry, Internal medicine, Chemotherapy, Pathology
- MeSH
- humans, withania, breast neoplasms, ethanol, doxorubicin, plant extracts, antineoplastic agents, chemotherapy, adjuvant, apoptosis, cell proliferation, drug synergism, mcf-7 cells
5 autores
- Emad M. Elzayat🇪🇬Cairo University
- Ghada E Elsamahy🇪🇬Cairo University
- Ghada H. Mansour🇪🇬Cairo University
- Ahmed Abdou El-Sherif🇪🇬Cairo University
- Nourhan Hassan🇪🇬Cairo University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Recent approaches in breast cancer treatment involve exploring natural extracts either as substitutes for traditional chemotherapeutic agents or as adjuvants to enhance their effectiveness. In this context, ethanolic extracts from Withania Somnifera (WS) and Arctium Lappa (AL) have gained attention for their potential anticancer properties across various cancer types.
Objective
This study aimed to investigate the in vitro anticancer efficacy of ethanolic extracts from both WS and AL in the MCF7 breast cancer cell line.
Methods
The study encompassed assessments of total antioxidant activity, total flavonoids, total phenolic compounds, and cytotoxicity for each extract. Unraveling the molecular mechanisms underlying the action of these extracts involved Real-time PCR and flow cytometry to analyze apoptotic markers and cell cycle dynamics, respectively.
Results
Results indicated that the WS ethanolic extract exhibited better efficacy, especially in terms of IC50. To explore its potential as an adjuvant with doxorubicin (DOX) in breast cancer therapy, 16 non-constant combination ratios were tested. The combination of 1/2 WS to 1/4 DOX, with a combination index (CI) of -0.229 was selected for further downstream molecular analysis. Gene expression analysis revealed a significant upregulation (p < 0.05) of P53, Cas3, Cas7, and Bax. Flow cytometric analysis further highlighted cell cycle arrest at the S phase. Additionally, the study explored the synergistic inhibitory effects of WS and DOX on key enzymes in the glycolytic pathway, namely, pyruvate kinase and aldolase.
Conclusion
In conclusion, the ethanolic extract of WS demonstrated a synergistic effect as an adjuvant with DOX, showing promise as a combination therapy for breast cancer.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.